Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
GateRouter
Smartly choose from 40+ AI models, with 0% extra fees
#TradFi交易分享挑战
#TradFiTradeShareChallenge
#mrna
$MRNA MRNA began to pull strong focus again inside the biotech group in the recent period. Good data flow for the mRNA-based flu shot and a new FDA review step made volume rise in the share. The firm’s cancer care work and bug-control projects also back the mid-term outlook.
At this stage price finds balance near the 48 zone. The 46.5 zone works like the main short-run guard area. As long as it holds above this part, the 51 and 54 zones can turn into goals again. If a high-volume break comes above 54, a firmer drive can form in the mid-term.
My trade idea:
• Careful entry in the 47 — 48 part • Think of adding size on a high-volume break above 51 • Cut risk if a close shows under 46
Push-back zones:
• 51 • 54 • 58
Guard zones:
• 46.5 • 44 • 41
Things to keep in mind:
• FDA steps can make hard swings in the share • Trial results hit price right away • The biotech group holds high risk, so leverage size should be set in a balanced way
Firm side:
MRNA is one of the large biotech firms building mRNA-based shots and care tech. With a flu shot, cancer care work, and bug-control projects, it has a strong research web in the field. The AI-aided drug build process is now one of the main drivers of the long-term outlook.
The chart view keeps its recovery phase for now. As long as volume holds, the room for an up move stays open.